HBM BioVentures

HBM BioVentures is a Swiss venture capital firm specializing in investments within the global healthcare sector, focusing on biotechnology, medical technology, diagnostics, therapeutics, and digital health. The firm primarily targets private companies with high value-creation potential, investing in both early-stage and growth-stage companies. HBM BioVentures is listed on the SIX Swiss Exchange under the ticker symbol HBMN.

The firm's investment strategy emphasizes emerging companies that are not yet publicly listed, with a significant portion of its portfolio dedicated to private companies. This approach has enabled HBM BioVentures to establish a distinctive market position in the healthcare investment landscape. The firm maintains a broad shareholder base and has a global presence, with investments spanning across various countries.

HBM BioVentures has a track record of over 100 investments, resulting in more than 60 trade sales and IPOs, demonstrating significant value creation. The firm's team of experienced professionals sources, analyzes, and engages in private and public healthcare investments, supporting the growth of portfolio companies through all stages of development. Investments typically range between USD 5 million and 50 million, reflecting the firm's commitment to fostering innovation and growth in the healthcare sector.